Pfizer Inc (NYSE:PFE) stock rose 2.98% (As on February 5, 11:21:47 AM UTC-4, Source: Google Finance) after the company reported fourth-quarter earnings and revenue that topped analyst estimates, driven by strong sales of its non-COVID products. Pfizer remains on track to deliver $4.5 billion in net cost savings by the end of 2025 from its ongoing realignment program. Fourth-quarter 2024 Comirnaty revenues of $3.4 billion decreased $2.0 billion, or 38%, operationally compared with the prior-year quarter, driven primarily by fewer COVID-19 vaccinations globally as well as lower contracted doses. Fourth-quarter 2024 Paxlovid revenues of $727 million increased $3.9 billion operationally compared with $(3.1) billion of revenues recorded in the prior-year quarter, primarily driven by the transition to traditional commercial market sales in the U.S. including a one-time, non-cash revenue reversal of $3.5 billion recorded in fourth-quarter 2023.

Moreover, Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 60% operationally, driven largely by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets, as well as increased affordability in the U.S. Eliquis globally, up 13% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets. Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower net price in the U.S. due to unfavorable changes in channel mix; and Xtandi, up 24% operationally, driven primarily by strong demand due to uptake of the non-metastatic castration-sensitive prostate cancer (nmCSPC) indication following approval in the fourth quarter of 2023 and increased affordability in the U.S.

PFE in the fourth quarter of FY 24 has reported the adjusted earnings per share of 63 cents, beating the analysts’ estimates for the adjusted earnings per share of 48 cents. The company had reported the adjusted revenue growth of 22 percent to $17.8 billion in the fourth quarter of FY 24, beating the analysts’ estimates for revenue of $17.28 billion. Excluding contributions from COVID-19 products Paxlovid and Comirnaty, Q4 revenues grew 11% operationally year-over-year to $13.7 billion. This growth was fueled by strong performances from the Vyndaqel family, Eliquis, and newly acquired Seagen products.

For 2025, Pfizer said it expects $2.80-$3.00 in adjusted EPS and revenue between $61-64 billion.